Calls
1
Rajesh Kumar
Senior Global Life Science and Healthcare Analyst, HSBC
Win Rate
-
return
-
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Feb 09
$1046.48
-
Eli Lilly has a second-market advantage with better labels and launch pricing, and has guided to about 25% growth next year versus Novo Nordisk's roughly 9% decline. Both face U.S. pricing pressure, but Novo's exposure to Wegovy generics and the need to reinvent next-generation drugs make it less attractive.
GLP-1 / Obesity
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Rajesh Kumar has 1 trade ideas tracked on Buzzberg across 1 tickers since February 2026.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
